Does the media favor RIGL or BCRX?

In the previous week, BioCryst Pharmaceuticals had 7 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 9 mentions for BioCryst Pharmaceuticals and 2 mentions for Rigel Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.06 beat Rigel Pharmaceuticals' score of 0.62 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rigel Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioCryst Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RIGL or ZBIO?

In the previous week, Zenas BioPharma had 4 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 6 mentions for Zenas BioPharma and 2 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.62 beat Zenas BioPharma's score of 0.57 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rigel Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RIGL or INVA?

In the previous week, Innoviva had 1 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 3 mentions for Innoviva and 2 mentions for Rigel Pharmaceuticals. Innoviva's average media sentiment score of 1.37 beat Rigel Pharmaceuticals' score of 0.62 indicating that Innoviva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rigel Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Innoviva 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RIGL or NVAX?

In the previous week, Novavax had 14 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 16 mentions for Novavax and 2 mentions for Rigel Pharmaceuticals. Novavax's average media sentiment score of 0.88 beat Rigel Pharmaceuticals' score of 0.62 indicating that Novavax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rigel Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novavax 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer MNKD or RIGL?

In the previous week, MannKind had 3 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 5 mentions for MannKind and 2 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.62 beat MannKind's score of 0.55 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rigel Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Rigel Pharmaceuticals (RIGL) Competitors

$40.62 -0.55 (-1.33%)

As of 03:43 PM Eastern

Compare

RIGL vs. BCRX, ZBIO, INVA, NVAX, and MNKD

Should you buy Rigel Pharmaceuticals stock or one of its competitors? MarketBeat compares Rigel Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rigel Pharmaceuticals include BioCryst Pharmaceuticals (BCRX), Zenas BioPharma (ZBIO), Innoviva (INVA), Novavax (NVAX), and MannKind (MNKD). These companies are all part of the "biotechnology" industry.

How does Rigel Pharmaceuticals compare to BioCryst Pharmaceuticals?

Rigel Pharmaceuticals (NASDAQ:RIGL) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 10.5% of Rigel Pharmaceuticals shares are owned by company insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Rigel Pharmaceuticals has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market.

In the previous week, BioCryst Pharmaceuticals had 7 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 9 mentions for BioCryst Pharmaceuticals and 2 mentions for Rigel Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.06 beat Rigel Pharmaceuticals' score of 0.62 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rigel Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioCryst Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rigel Pharmaceuticals has a net margin of 121.50% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Rigel Pharmaceuticals' return on equity of 47.99% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	121.50%	47.99%	32.40%
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%

Rigel Pharmaceuticals currently has a consensus price target of $54.50, indicating a potential upside of 34.16%. BioCryst Pharmaceuticals has a consensus price target of $20.80, indicating a potential upside of 119.53%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
BioCryst Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67

Rigel Pharmaceuticals has higher earnings, but lower revenue than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$294.28M	2.55	$367.02M	$18.72	2.17
BioCryst Pharmaceuticals	$874.84M	2.75	$263.86M	-$1.78	N/A

Summary

BioCryst Pharmaceuticals beats Rigel Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Rigel Pharmaceuticals compare to Zenas BioPharma?

Rigel Pharmaceuticals (NASDAQ:RIGL) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

In the previous week, Zenas BioPharma had 4 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 6 mentions for Zenas BioPharma and 2 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.62 beat Zenas BioPharma's score of 0.57 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rigel Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rigel Pharmaceuticals has a net margin of 121.50% compared to Zenas BioPharma's net margin of 0.00%. Rigel Pharmaceuticals' return on equity of 47.99% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	121.50%	47.99%	32.40%
Zenas BioPharma	N/A	-99.99%	-58.06%

Rigel Pharmaceuticals presently has a consensus price target of $54.50, suggesting a potential upside of 34.16%. Zenas BioPharma has a consensus price target of $44.29, suggesting a potential upside of 50.87%. Given Zenas BioPharma's stronger consensus rating and higher probable upside, analysts clearly believe Zenas BioPharma is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Rigel Pharmaceuticals has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.96, suggesting that its stock price is 196% less volatile than the broader market.

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 10.5% of Rigel Pharmaceuticals shares are owned by company insiders. Comparatively, 22.0% of Zenas BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Rigel Pharmaceuticals has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$294.28M	2.55	$367.02M	$18.72	2.17
Zenas BioPharma	N/A	N/A	-$377.74M	-$8.47	N/A

Summary

Rigel Pharmaceuticals beats Zenas BioPharma on 10 of the 15 factors compared between the two stocks.

How does Rigel Pharmaceuticals compare to Innoviva?

Rigel Pharmaceuticals (NASDAQ:RIGL) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

Rigel Pharmaceuticals has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market. Comparatively, Innoviva has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market.

In the previous week, Innoviva had 1 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 3 mentions for Innoviva and 2 mentions for Rigel Pharmaceuticals. Innoviva's average media sentiment score of 1.37 beat Rigel Pharmaceuticals' score of 0.62 indicating that Innoviva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rigel Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Innoviva	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rigel Pharmaceuticals presently has a consensus price target of $54.50, indicating a potential upside of 34.16%. Innoviva has a consensus price target of $36.20, indicating a potential upside of 65.56%. Given Innoviva's stronger consensus rating and higher possible upside, analysts clearly believe Innoviva is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Rigel Pharmaceuticals has higher earnings, but lower revenue than Innoviva. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$294.28M	2.55	$367.02M	$18.72	2.17
Innoviva	$411.33M	3.92	$271.17M	$6.01	3.64

Rigel Pharmaceuticals has a net margin of 121.50% compared to Innoviva's net margin of 119.89%. Rigel Pharmaceuticals' return on equity of 47.99% beat Innoviva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	121.50%	47.99%	32.40%
Innoviva	119.89%	33.33%	22.67%

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.1% of Innoviva shares are owned by institutional investors. 10.5% of Rigel Pharmaceuticals shares are owned by insiders. Comparatively, 2.0% of Innoviva shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Innoviva beats Rigel Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Rigel Pharmaceuticals compare to Novavax?

Rigel Pharmaceuticals (NASDAQ:RIGL) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

Rigel Pharmaceuticals has a net margin of 121.50% compared to Novavax's net margin of -14.73%. Rigel Pharmaceuticals' return on equity of 47.99% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	121.50%	47.99%	32.40%
Novavax	-14.73%	-14.82%	1.23%

Novavax has higher revenue and earnings than Rigel Pharmaceuticals. Novavax is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$294.28M	2.55	$367.02M	$18.72	2.17
Novavax	$1.12B	1.23	$440.30M	-$0.58	N/A

Rigel Pharmaceuticals has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market. Comparatively, Novavax has a beta of 2.43, indicating that its share price is 143% more volatile than the broader market.

Rigel Pharmaceuticals currently has a consensus target price of $54.50, indicating a potential upside of 34.16%. Novavax has a consensus target price of $13.00, indicating a potential upside of 54.49%. Given Novavax's stronger consensus rating and higher probable upside, analysts plainly believe Novavax is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.40

66.2% of Rigel Pharmaceuticals shares are held by institutional investors. Comparatively, 53.0% of Novavax shares are held by institutional investors. 10.5% of Rigel Pharmaceuticals shares are held by company insiders. Comparatively, 1.6% of Novavax shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Novavax had 14 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 16 mentions for Novavax and 2 mentions for Rigel Pharmaceuticals. Novavax's average media sentiment score of 0.88 beat Rigel Pharmaceuticals' score of 0.62 indicating that Novavax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rigel Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novavax	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Novavax beats Rigel Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Rigel Pharmaceuticals compare to MannKind?

MannKind (NASDAQ:MNKD) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

49.6% of MannKind shares are owned by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 2.6% of MannKind shares are owned by company insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

MannKind has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market.

In the previous week, MannKind had 3 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 5 mentions for MannKind and 2 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.62 beat MannKind's score of 0.55 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rigel Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MannKind presently has a consensus target price of $8.97, indicating a potential upside of 119.02%. Rigel Pharmaceuticals has a consensus target price of $54.50, indicating a potential upside of 34.16%. Given MannKind's stronger consensus rating and higher possible upside, equities research analysts plainly believe MannKind is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Rigel Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Rigel Pharmaceuticals has a net margin of 121.50% compared to MannKind's net margin of -6.63%. Rigel Pharmaceuticals' return on equity of 47.99% beat MannKind's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-6.63%	-11.21%	-3.92%
Rigel Pharmaceuticals	121.50%	47.99%	32.40%

Rigel Pharmaceuticals has lower revenue, but higher earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	3.63	$5.86M	-$0.07	N/A
Rigel Pharmaceuticals	$294.28M	2.55	$367.02M	$18.72	2.17

Summary

Rigel Pharmaceuticals beats MannKind on 10 of the 16 factors compared between the two stocks.

Get Rigel Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RIGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RIGL vs. The Competition

Export

Metric	Rigel Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$750.16M	$3.00B	$6.79B	$12.62B
Dividend Yield	N/A	2.08%	2.68%	8.42%
P/E Ratio	2.17	19.36	27.11	24.33
Price / Sales	2.55	343.44	523.72	90.61
Price / Cash	6.13	56.83	48.59	59.39
Price / Book	1.88	4.25	10.85	6.31
Net Income	$367.02M	$65.13M	$3.59B	$331.45M
7 Day Performance	-5.26%	-2.22%	-1.34%	-0.04%
1 Month Performance	21.55%	2.49%	2.99%	-0.88%
1 Year Performance	114.94%	23.95%	28.94%	20.43%

Rigel Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RIGL Rigel Pharmaceuticals	3.8067 of 5 stars	$40.62 -1.3%	$54.50 +34.2%	+112.8%	$750.16M	$294.28M	2.17	160
BCRX BioCryst Pharmaceuticals	3.1883 of 5 stars	$10.17 +3.4%	$21.67 +113.0%	+8.7%	$2.50B	$874.84M	N/A	530	Positive News Analyst Forecast
ZBIO Zenas BioPharma	3.5162 of 5 stars	$26.45 -2.9%	$44.29 +67.4%	+124.5%	$1.72B	$10M	N/A	N/A
INVA Innoviva	3.7559 of 5 stars	$21.82 -2.2%	$36.20 +65.9%	+11.0%	$1.65B	$411.33M	3.63	100	Positive News
NVAX Novavax	2.1937 of 5 stars	$9.35 -4.0%	$13.00 +39.0%	+20.8%	$1.60B	$1.12B	N/A	1,990

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RIGL) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rigel Pharmaceuticals (RIGL) Competitors

RIGL vs. BCRX, ZBIO, INVA, NVAX, and MNKD

How does Rigel Pharmaceuticals compare to BioCryst Pharmaceuticals?

Summary

How does Rigel Pharmaceuticals compare to Zenas BioPharma?

Summary

How does Rigel Pharmaceuticals compare to Innoviva?

Summary

How does Rigel Pharmaceuticals compare to Novavax?

Summary

How does Rigel Pharmaceuticals compare to MannKind?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RIGL vs. The Competition

Rigel Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rigel Pharmaceuticals (RIGL) Competitors

RIGL vs. BCRX, ZBIO, INVA, NVAX, and MNKD

How does Rigel Pharmaceuticals compare to BioCryst Pharmaceuticals?

Do institutionals & insiders have more ownership in RIGL or BCRX?

Which has more risk and volatility, RIGL or BCRX?

Does the media favor RIGL or BCRX?

Is RIGL or BCRX more profitable?

Do analysts prefer RIGL or BCRX?

Which has better valuation and earnings, RIGL or BCRX?

Summary

How does Rigel Pharmaceuticals compare to Zenas BioPharma?

Does the media favor RIGL or ZBIO?

Is RIGL or ZBIO more profitable?

Do analysts prefer RIGL or ZBIO?

Which has more volatility & risk, RIGL or ZBIO?

Do insiders and institutionals have more ownership in RIGL or ZBIO?

Which has preferable earnings and valuation, RIGL or ZBIO?

Summary

How does Rigel Pharmaceuticals compare to Innoviva?

Which has more volatility & risk, RIGL or INVA?

Does the media favor RIGL or INVA?

Do analysts recommend RIGL or INVA?

Which has preferable valuation & earnings, RIGL or INVA?

Is RIGL or INVA more profitable?

Do insiders & institutionals believe in RIGL or INVA?

Summary

How does Rigel Pharmaceuticals compare to Novavax?

Is RIGL or NVAX more profitable?

Which has stronger earnings & valuation, RIGL or NVAX?

Which has more risk and volatility, RIGL or NVAX?

Do analysts rate RIGL or NVAX?

Do insiders & institutionals believe in RIGL or NVAX?

Does the media favor RIGL or NVAX?

Summary

How does Rigel Pharmaceuticals compare to MannKind?

Do institutionals & insiders believe in MNKD or RIGL?

Which has more volatility & risk, MNKD or RIGL?

Does the media prefer MNKD or RIGL?

Do analysts rate MNKD or RIGL?

Is MNKD or RIGL more profitable?

Which has stronger valuation & earnings, MNKD or RIGL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RIGL vs. The Competition

Rigel Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools